Melanoma (primary nd
To Order Contact us: stephen@expresspharmapulse.com
Melanoma tissue array |
ME483 |
TissueArray |
each |
EUR 270 |
Description: Melanoma tissue array, including TNM and clinical stage, 48 cases/48 cores, replaced by ME483a |
Melanoma (gp100) Protein |
20-abx263540 |
Abbexa |
-
EUR 994.80
-
EUR 493.20
-
EUR 644.40
|
|
|
Melanoma Antibody / PNL2 |
V3071-100UG |
NSJ Bioreagents |
100 ug |
EUR 349.3 |
Description: Anti-PNL2 is a novel melanoma marker monoclonal antibody, which has recently been introduced as an immunohistochemical reagent to stain melanocytes and tumors derived therefrom. The antigen recognized by PNL2 is different from Melan A and gp100. Its epitope is not destroyed by digestion with neuraminidase i.e. its epitope is not glycosylated. Anti-PNL2 may be most useful because of its high sensitivity for metastatic melanoma (87%), as opposed to 76% for anti-HMB45 and 82% for anti-MART-1. Anti-PNL2 labels intra-epidermal nevi while the dermal component of compound nevi are largely non-reactive with anti-PNL2. Antibodies against PNL2, MART-1 (Melan A) and HMB45 stain most clear cell sarcoma cells and a few cells in angiomyolipomas and lymphangioleiomyomatosis. Anti-PNL2 is a useful antibody for the identification of melanomas and clear cell sarcomas. Differential diagnosis is aided by the results from a panel of antibodies, including antibodies against HMB45, MART-1, tyrosinase, and MiTF. |
Melanoma Antibody / PNL2 |
V3071-20UG |
NSJ Bioreagents |
20 ug |
EUR 153.3 |
Description: Anti-PNL2 is a novel melanoma marker monoclonal antibody, which has recently been introduced as an immunohistochemical reagent to stain melanocytes and tumors derived therefrom. The antigen recognized by PNL2 is different from Melan A and gp100. Its epitope is not destroyed by digestion with neuraminidase i.e. its epitope is not glycosylated. Anti-PNL2 may be most useful because of its high sensitivity for metastatic melanoma (87%), as opposed to 76% for anti-HMB45 and 82% for anti-MART-1. Anti-PNL2 labels intra-epidermal nevi while the dermal component of compound nevi are largely non-reactive with anti-PNL2. Antibodies against PNL2, MART-1 (Melan A) and HMB45 stain most clear cell sarcoma cells and a few cells in angiomyolipomas and lymphangioleiomyomatosis. Anti-PNL2 is a useful antibody for the identification of melanomas and clear cell sarcomas. Differential diagnosis is aided by the results from a panel of antibodies, including antibodies against HMB45, MART-1, tyrosinase, and MiTF. |
Melanoma Antibody / PNL2 |
V3071IHC-7ML |
NSJ Bioreagents |
7 ml |
EUR 349.3 |
Description: Anti-PNL2 is a novel melanoma marker monoclonal antibody, which has recently been introduced as an immunohistochemical reagent to stain melanocytes and tumors derived therefrom. The antigen recognized by PNL2 is different from Melan A and gp100. Its epitope is not destroyed by digestion with neuraminidase i.e. its epitope is not glycosylated. Anti-PNL2 may be most useful because of its high sensitivity for metastatic melanoma (87%), as opposed to 76% for anti-HMB45 and 82% for anti-MART-1. Anti-PNL2 labels intra-epidermal nevi while the dermal component of compound nevi are largely non-reactive with anti-PNL2. Antibodies against PNL2, MART-1 (Melan A) and HMB45 stain most clear cell sarcoma cells and a few cells in angiomyolipomas and lymphangioleiomyomatosis. Anti-PNL2 is a useful antibody for the identification of melanomas and clear cell sarcomas. Differential diagnosis is aided by the results from a panel of antibodies, including antibodies against HMB45, MART-1, tyrosinase, and MiTF. |
Melanoma Antibody / PNL2 |
V3071SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 349.3 |
Description: Anti-PNL2 is a novel melanoma marker monoclonal antibody, which has recently been introduced as an immunohistochemical reagent to stain melanocytes and tumors derived therefrom. The antigen recognized by PNL2 is different from Melan A and gp100. Its epitope is not destroyed by digestion with neuraminidase i.e. its epitope is not glycosylated. Anti-PNL2 may be most useful because of its high sensitivity for metastatic melanoma (87%), as opposed to 76% for anti-HMB45 and 82% for anti-MART-1. Anti-PNL2 labels intra-epidermal nevi while the dermal component of compound nevi are largely non-reactive with anti-PNL2. Antibodies against PNL2, MART-1 (Melan A) and HMB45 stain most clear cell sarcoma cells and a few cells in angiomyolipomas and lymphangioleiomyomatosis. Anti-PNL2 is a useful antibody for the identification of melanomas and clear cell sarcomas. Differential diagnosis is aided by the results from a panel of antibodies, including antibodies against HMB45, MART-1, tyrosinase, and MiTF. |
Melanoma, 48 cases (1.5mm) |
MEL961 |
Pantomics |
1 |
EUR 372 |
Description: Melanoma tissue array containing 12 cases of normal epithelium, nevus and carcinoma of the skin, and 36 cases of primary (26 cases) and metastatic (10 cases) melanomas in duplicates. |
TnI (Primary) Antibody |
abx018056-100ug |
Abbexa |
100 ug |
EUR 410.4 |
|
Primary Human Neurons |
HNC001 |
Neuromics |
300,000 Cyroperserved Cells |
EUR 1467.6 |
Melanoma (skin cancer) Exosome |
P141-MN |
101Bio |
- |
Ask for price |
Melanoma Marker(PNL2) Antibody |
BNC800894-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against Melanoma Marker(PNL2), CF680 conjugate, Concentration: 0.1mg/mL |
Melanoma Marker(PNL2) Antibody |
BNC800894-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against Melanoma Marker(PNL2), CF680 conjugate, Concentration: 0.1mg/mL |
Melanoma Marker(PNL2) Antibody |
BNC810894-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against Melanoma Marker(PNL2), CF680R conjugate, Concentration: 0.1mg/mL |
Melanoma Marker(PNL2) Antibody |
BNC810894-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against Melanoma Marker(PNL2), CF680R conjugate, Concentration: 0.1mg/mL |
Melanoma Marker(PNL2) Antibody |
BNC940894-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against Melanoma Marker(PNL2), CF594 conjugate, Concentration: 0.1mg/mL |
Melanoma Marker(PNL2) Antibody |
BNC940894-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against Melanoma Marker(PNL2), CF594 conjugate, Concentration: 0.1mg/mL |
Melanoma Marker(PNL2) Antibody |
BNC700894-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against Melanoma Marker(PNL2), CF770 conjugate, Concentration: 0.1mg/mL |
Melanoma Marker(PNL2) Antibody |
BNC700894-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against Melanoma Marker(PNL2), CF770 conjugate, Concentration: 0.1mg/mL |
Melanoma Marker(PNL2) Antibody |
BNC880894-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against Melanoma Marker(PNL2), CF488A conjugate, Concentration: 0.1mg/mL |
Melanoma Marker(PNL2) Antibody |
BNC880894-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against Melanoma Marker(PNL2), CF488A conjugate, Concentration: 0.1mg/mL |
Melanoma Marker(PNL2) Antibody |
BNC050894-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against Melanoma Marker(PNL2), CF405M conjugate, Concentration: 0.1mg/mL |
Melanoma Marker(PNL2) Antibody |
BNC050894-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against Melanoma Marker(PNL2), CF405M conjugate, Concentration: 0.1mg/mL |
Melanoma Marker(PNL2) Antibody |
BNC040894-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against Melanoma Marker(PNL2), CF405S conjugate, Concentration: 0.1mg/mL |
Melanoma Marker(PNL2) Antibody |
BNC040894-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against Melanoma Marker(PNL2), CF405S conjugate, Concentration: 0.1mg/mL |
Melanoma Marker(PNL2) Antibody |
BNC400894-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against Melanoma Marker(PNL2), CF640R conjugate, Concentration: 0.1mg/mL |
Melanoma Marker(PNL2) Antibody |
BNC400894-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against Melanoma Marker(PNL2), CF640R conjugate, Concentration: 0.1mg/mL |
Melanoma Marker(PNL2) Antibody |
BNCB0894-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against Melanoma Marker(PNL2), Biotin conjugate, Concentration: 0.1mg/mL |
Melanoma Marker(PNL2) Antibody |
BNCB0894-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against Melanoma Marker(PNL2), Biotin conjugate, Concentration: 0.1mg/mL |
Melanoma Marker(PNL2) Antibody |
BNCAP0894-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against Melanoma Marker(PNL2), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
Melanoma Marker(PNL2) Antibody |
BNCAP0894-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against Melanoma Marker(PNL2), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
Melanoma Marker(PNL2) Antibody |
BNCA0894-250 |
Biotium |
250uL |
EUR 459.6 |
Description: Primary antibody against Melanoma Marker(PNL2), APC conjugate, Concentration: 0.1mg/mL |
Melanoma Marker(PNL2) Antibody |
BNCR0894-250 |
Biotium |
250uL |
EUR 459.6 |
Description: Primary antibody against Melanoma Marker(PNL2), RPE conjugate, Concentration: 0.1mg/mL |
Melanoma Marker(PNL2) Antibody |
BNCP0894-250 |
Biotium |
250uL |
EUR 459.6 |
Description: Primary antibody against Melanoma Marker(PNL2), PerCP conjugate, Concentration: 0.1mg/mL |
Melanoma Marker(PNL2) Antibody |
BNUM0894-50 |
Biotium |
50uL |
EUR 474 |
Description: Primary antibody against Melanoma Marker(PNL2), 1mg/mL |
Melanoma Marker(PNL2) Antibody |
BNCH0894-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against Melanoma Marker(PNL2), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
Melanoma Marker(PNL2) Antibody |
BNCH0894-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against Melanoma Marker(PNL2), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
Melanoma Marker(PNL2) Antibody |
BNUB0894-100 |
Biotium |
100uL |
EUR 250.8 |
Description: Primary antibody against Melanoma Marker(PNL2), Concentration: 0.2mg/mL |
Melanoma Marker(PNL2) Antibody |
BNUB0894-500 |
Biotium |
500uL |
EUR 549.6 |
Description: Primary antibody against Melanoma Marker(PNL2), Concentration: 0.2mg/mL |
Melanoma Marker(PNL2) Antibody |
BNC610894-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against Melanoma Marker(PNL2), CF660R conjugate, Concentration: 0.1mg/mL |
Melanoma Marker(PNL2) Antibody |
BNC610894-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against Melanoma Marker(PNL2), CF660R conjugate, Concentration: 0.1mg/mL |
Melanoma Marker(PNL2) Antibody |
BNC550894-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against Melanoma Marker(PNL2), CF555 conjugate, Concentration: 0.1mg/mL |
Melanoma Marker(PNL2) Antibody |
BNC550894-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against Melanoma Marker(PNL2), CF555 conjugate, Concentration: 0.1mg/mL |
Melanoma Marker(PNL2) Antibody |
BNC430894-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against Melanoma Marker(PNL2), CF543 conjugate, Concentration: 0.1mg/mL |
Melanoma Marker(PNL2) Antibody |
BNC430894-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against Melanoma Marker(PNL2), CF543 conjugate, Concentration: 0.1mg/mL |
Melanoma Marker(PNL2) Antibody |
BNC680894-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against Melanoma Marker(PNL2), CF568 conjugate, Concentration: 0.1mg/mL |
Melanoma Marker(PNL2) Antibody |
BNC680894-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against Melanoma Marker(PNL2), CF568 conjugate, Concentration: 0.1mg/mL |
Melanoma Marker(PNL2) Antibody |
BNC470894-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against Melanoma Marker(PNL2), CF647 conjugate, Concentration: 0.1mg/mL |
Melanoma Marker(PNL2) Antibody |
BNC470894-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against Melanoma Marker(PNL2), CF647 conjugate, Concentration: 0.1mg/mL |
PMEL17 / Melanoma gp100 Antibody |
RQ4546 |
NSJ Bioreagents |
100ug |
EUR 356.15 |
Description: This gene is mapped to 12q13.2. It encodes a melanocyte-specific type I transmembrane glycoprotein. The encoded protein is enriched in melanosomes, which are the melanin-producing organelles in melanocytes, and plays an essential role in the structural organization of premelanosomes. This protein is involved in generating internal matrix fibers that define the transition from Stage I to Stage II melanosomes. This protein undergoes a complex pattern of prosttranslational processing and modification that is essential to the proper functioning of the protein. A secreted form of this protein that is released by proteolytic ectodomain shedding may be used as a melanoma-specific serum marker. Alternate splicing results in multiple transcript variants. |
PMEL17 / Melanoma gp100 Antibody |
V3472-100UG |
NSJ Bioreagents |
100 ug |
EUR 349.3 |
Description: The gp100 molecule is a 100kDa glycosylated protein that is cleaved into a small (26kDa) carboxy-terminal fragment and a larger amino- terminal section (60-64 kDa), which is subsequently cleaved to generate 26kDa and 34-38kDa. By immunohistochemistry, it specifically recognizes a protein in melanocytes and melanomas. This MAb reacts with junctional and blue nevus cells and variably with fetal and neonatal melanocytes. Intradermal nevi, normal adult melanocytes, and non-melanocytic cells are negative. It does not stain tumor cells of epithelial, lymphoid, glial, or mesenchymal origin. Metastatic amelanotic melanoma can often be confused with a variety of poorly differentiated carcinomas, large cell lymphomas, and sarcomas using H E stains alone. It is also difficult to differentiate melanoma from spindle cell carcinomas and various types of mesenchymal neoplasms. This MAb stains fetal and neonatal melanocytes, junctional and blue nevus cells, and malignant melanoma. This MAb also stains Angiomyolipoma (PEComa). |
PMEL17 / Melanoma gp100 Antibody |
V3472-20UG |
NSJ Bioreagents |
20 ug |
EUR 153.3 |
Description: The gp100 molecule is a 100kDa glycosylated protein that is cleaved into a small (26kDa) carboxy-terminal fragment and a larger amino- terminal section (60-64 kDa), which is subsequently cleaved to generate 26kDa and 34-38kDa. By immunohistochemistry, it specifically recognizes a protein in melanocytes and melanomas. This MAb reacts with junctional and blue nevus cells and variably with fetal and neonatal melanocytes. Intradermal nevi, normal adult melanocytes, and non-melanocytic cells are negative. It does not stain tumor cells of epithelial, lymphoid, glial, or mesenchymal origin. Metastatic amelanotic melanoma can often be confused with a variety of poorly differentiated carcinomas, large cell lymphomas, and sarcomas using H E stains alone. It is also difficult to differentiate melanoma from spindle cell carcinomas and various types of mesenchymal neoplasms. This MAb stains fetal and neonatal melanocytes, junctional and blue nevus cells, and malignant melanoma. This MAb also stains Angiomyolipoma (PEComa). |
Melanoma (primary nd